- Home
- RS vs ITCI Comparison
RS vs ITCI Comparison
Compare RS & ITCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RS
- ITCI
- Stock Information
- Founded
- RS 1939
- ITCI 2002
- Country
- RS United States
- ITCI United States
- Employees
- RS N/A
- ITCI N/A
- Industry
- RS Metal Fabrications
- ITCI Biotechnology: Pharmaceutical Preparations
- Sector
- RS Industrials
- ITCI Health Care
- Exchange
- RS Nasdaq
- ITCI Nasdaq
- Market Cap
- RS 15.7B
- ITCI 13.5B
- IPO Year
- RS 1994
- ITCI N/A
- Fundamental
- Price
- RS $300.93
- ITCI $128.60
- Analyst Decision
- RS Hold
- ITCI Buy
- Analyst Count
- RS 5
- ITCI 13
- Target Price
- RS $343.00
- ITCI $103.92
- AVG Volume (30 Days)
- RS 402.0K
- ITCI 2.2M
- Earning Date
- RS 02-19-2025
- ITCI 02-21-2025
- Dividend Yield
- RS 1.59%
- ITCI N/A
- EPS Growth
- RS N/A
- ITCI N/A
- EPS
- RS 15.56
- ITCI N/A
- Revenue
- RS $13,835,000,000.00
- ITCI $613,728,000.00
- Revenue This Year
- RS N/A
- ITCI $48.28
- Revenue Next Year
- RS $1.29
- ITCI $37.34
- P/E Ratio
- RS $19.37
- ITCI N/A
- Revenue Growth
- RS N/A
- ITCI 46.08
- 52 Week Low
- RS $256.98
- ITCI $63.30
- 52 Week High
- RS $342.20
- ITCI $128.77
- Technical
- Relative Strength Index (RSI)
- RS 60.47
- ITCI 83.90
- Support Level
- RS $292.89
- ITCI $126.88
- Resistance Level
- RS $310.98
- ITCI $128.19
- Average True Range (ATR)
- RS 6.78
- ITCI 0.41
- MACD
- RS 1.32
- ITCI -1.30
- Stochastic Oscillator
- RS 68.04
- ITCI 91.01
About RS Reliance Steel & Aluminum Co. (DE)
Reliance Inc is a diversified metal solutions provider and metals service center company. It provides value-added metals processing services and distributes.
About ITCI Intra-Cellular Therapies Inc.
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.